Cargando…
Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines
HER2 is overexpressed in 25–30% of breast cancers, and approximately 30% of HER2-positive breast cancers metastasize to the brain. Although the incidence of brain metastasis in HER2-positive breast cancer is high, previous studies have been mainly based on cell lines of the triple-negative subtype,...
Autores principales: | Kuroiwa, Yuka, Nakayama, Jun, Adachi, Chihiro, Inoue, Takafumi, Watanabe, Shinya, Semba, Kentaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408688/ https://www.ncbi.nlm.nih.gov/pubmed/32640677 http://dx.doi.org/10.3390/cancers12071811 |
Ejemplares similares
-
The In Vivo Selection Method in Breast Cancer Metastasis
por: Nakayama, Jun, et al.
Publicado: (2021) -
Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015) -
Aberrant accumulation of NIK promotes tumor growth by dysregulating translation and post-translational modifications in breast cancer
por: Hayashi, Yusuke, et al.
Publicado: (2023) -
Long-term hemodynamic changes in cerebral proliferative angiopathy presenting with intracranial hemorrhage: illustrative case
por: Saito, Takaya, et al.
Publicado: (2023) -
Ocular expression of cyclin‐dependent kinase 5 in patients with proliferative diabetic retinopathy
por: Sano, Hiroki, et al.
Publicado: (2021)